The Association of Avoidant/Restrictive Food Intake Disorder (ARFID) and Neurogastroenterology Disorders (Including Disorders of Gut-Brain Interaction [DGBI]): A Scoping Review.

IF 2.9 3区医学 Q1 CLINICAL NEUROLOGY

Neurogastroenterology and Motility Pub Date : 2025-09-01 Epub Date: 2025-03-30 DOI:10.1111/nmo.70039

Hiba Mikhael-Moussa, Valérie Bertrand, Emeline Lejeune, Claire Dupont, Alexandra Aupetit, Najate Achamrah, Chloé Melchior

{"title":"The Association of Avoidant/Restrictive Food Intake Disorder (ARFID) and Neurogastroenterology Disorders (Including Disorders of Gut-Brain Interaction [DGBI]): A Scoping Review.","authors":"Hiba Mikhael-Moussa, Valérie Bertrand, Emeline Lejeune, Claire Dupont, Alexandra Aupetit, Najate Achamrah, Chloé Melchior","doi":"10.1111/nmo.70039","DOIUrl":null,"url":null,"abstract":"Background: Patients with neurogastroenterology disorders like disorders of gut-brain interaction (DGBI) and gastrointestinal (GI) motility disorders often adopt restrictive diets to manage symptoms. Without professional guidance, these patients may risk developing avoidant/restrictive food intake disorder (ARFID), potentially affecting their physical and mental health.Purpose: This scoping review aimed to explore the prevalence of ARFID in patients with neurogastroenterology disorders and vice versa, the direction of their association, potential risk factors, and available treatments.Methods: Following PRISMA-ScR guidelines, we searched PubMed, Web of Science, and Cochrane. Abstracts were screened for eligibility by two independent reviewers.Key results: Eighteen studies met our inclusion criteria. The prevalence of ARFID symptoms in neurogastroenterology patients ranged from 10% to 80%, while the prevalence of neurogastroenterology disorders and related GI symptoms in ARFID patients ranged from 7% to 60%. Findings on the direction of the association between eating difficulties and GI symptom occurrence were conflicting. Patients with ARFID-neurogastroenterology disorder overlap were more likely to be female, have a lower BMI, higher anxiety and depression levels, and poorer quality of life. Two small studies evaluating treatment for this overlap suggested promising effects of cognitive behavioral therapy (CBT).Conclusions and inferences: This review highlights heterogeneity in study designs and questions the suitability of ARFID assessment tools in this context. It also underscores gaps in understanding the underlying pathophysiology and treatment approaches. Future research should prioritize validating ARFID screening tools specific to this population and standardizing study methodologies. Improved understanding of this overlap will help healthcare professionals improve management strategies and patient outcomes.","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70039"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351358/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurogastroenterology and Motility","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/nmo.70039","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with neurogastroenterology disorders like disorders of gut-brain interaction (DGBI) and gastrointestinal (GI) motility disorders often adopt restrictive diets to manage symptoms. Without professional guidance, these patients may risk developing avoidant/restrictive food intake disorder (ARFID), potentially affecting their physical and mental health.

Purpose: This scoping review aimed to explore the prevalence of ARFID in patients with neurogastroenterology disorders and vice versa, the direction of their association, potential risk factors, and available treatments.

Methods: Following PRISMA-ScR guidelines, we searched PubMed, Web of Science, and Cochrane. Abstracts were screened for eligibility by two independent reviewers.

Key results: Eighteen studies met our inclusion criteria. The prevalence of ARFID symptoms in neurogastroenterology patients ranged from 10% to 80%, while the prevalence of neurogastroenterology disorders and related GI symptoms in ARFID patients ranged from 7% to 60%. Findings on the direction of the association between eating difficulties and GI symptom occurrence were conflicting. Patients with ARFID-neurogastroenterology disorder overlap were more likely to be female, have a lower BMI, higher anxiety and depression levels, and poorer quality of life. Two small studies evaluating treatment for this overlap suggested promising effects of cognitive behavioral therapy (CBT).

Conclusions and inferences: This review highlights heterogeneity in study designs and questions the suitability of ARFID assessment tools in this context. It also underscores gaps in understanding the underlying pathophysiology and treatment approaches. Future research should prioritize validating ARFID screening tools specific to this population and standardizing study methodologies. Improved understanding of this overlap will help healthcare professionals improve management strategies and patient outcomes.

查看原文本刊更多论文

回避/限制性食物摄入障碍（ARFID）与神经胃肠疾病（包括肠脑相互作用障碍[DGBI]）的关联：范围综述

背景：神经胃肠疾病如肠-脑相互作用障碍（DGBI）和胃肠道运动障碍（GI）患者通常采用限制性饮食来控制症状。如果没有专业指导，这些患者可能会有发展为回避/限制性食物摄入障碍（ARFID）的风险，潜在地影响他们的身心健康。目的：本综述旨在探讨ARFID在神经胃肠疾病患者中的患病率，以及ARFID在神经胃肠疾病患者中的患病率、ARFID的相关性、潜在危险因素和可用治疗方法。方法：按照PRISMA-ScR指南，我们检索PubMed、Web of Science和Cochrane。摘要由两名独立审稿人进行筛选。关键结果：18项研究符合我们的纳入标准。ARFID患者中ARFID症状的患病率从10%到80%不等，而ARFID患者中神经胃肠疾病和相关胃肠道症状的患病率从7%到60%不等。关于进食困难和胃肠道症状发生之间的关系方向的研究结果是相互矛盾的。arfid -神经胃肠疾病重叠的患者更可能是女性，BMI较低，焦虑和抑郁水平较高，生活质量较差。两项评估这种重叠的治疗方法的小型研究表明，认知行为疗法（CBT）的效果很有希望。结论和推论：这篇综述强调了研究设计的异质性，并质疑ARFID评估工具在这种情况下的适用性。它也强调了在理解潜在病理生理学和治疗方法方面的差距。未来的研究应优先验证针对这一人群的ARFID筛选工具，并使研究方法标准化。提高对这种重叠的理解将有助于医疗保健专业人员改进管理策略和患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurogastroenterology and Motility 医学-临床神经学

CiteScore

7.80

自引率

8.60%

发文量

178

审稿时长

3-6 weeks

期刊介绍： Neurogastroenterology & Motility (NMO) is the official Journal of the European Society of Neurogastroenterology & Motility (ESNM) and the American Neurogastroenterology and Motility Society (ANMS). It is edited by James Galligan, Albert Bredenoord, and Stephen Vanner. The editorial and peer review process is independent of the societies affiliated to the journal and publisher: Neither the ANMS, the ESNM or the Publisher have editorial decision-making power. Whenever these are relevant to the content being considered or published, the editors, journal management committee and editorial board declare their interests and affiliations.